Whalesbook
🟢 SCENARIO A: For Earnings, Buybacks, or Financial Updates
📉 The Financial Deep Dive
Strides Pharma Science Limited has reported a robust Q3 FY'26 performance, marked by its highest-ever quarterly EBITDA of ₹236 crores, representing a significant 12% year-on-year increase. This surge in profitability was complemented by an expansion in EBITDA margins to a healthy 19.8%. Operational Profit After Tax (PAT) demonstrated substantial growth, climbing 39% year-on-year to ₹128 crores, outperforming the entire operational PAT of FY'25 within the first nine months of FY'26.
Gross margins reached 59.8%, with management expressing confidence in maintaining this within a sustainable range of 58-60%. This improved financial health is reflected in key balance sheet metrics: Debt/EBITDA stands at a manageable 1.59x, and Return on Capital Employed (ROCE) improved to 15.8%. The company reported a Net Debt of ₹1,436 crores, achieving a constant currency reduction of ₹169 crores over the nine-month period. Capital expenditure for the quarter amounted to ₹284 crores, primarily allocated towards product rights.
🗣️ The Grill
While the overall financial report was positive, the US business presented a mixed picture, remaining largely flat at $70 million. Management attributed this stagnation to several transient factors: a delayed flu season impacting sales, intensified market competition, slower quota allocations for control substances, and the strategic discontinuation of eight non-profitable products. Despite these short-term challenges, the company reiterated its medium-term outlook for the US, targeting $400 million in revenue by FY'28. This projection hinges on relaunching dormant products and strategic investments in complex areas such as control substances and nasal sprays. Key leadership changes, including the appointment of Peter Hardwick as CEO of North American Business, signal a renewed focus on this critical market.
🚩 Risks & Outlook
The primary focus for investors will be the execution of the US market recovery strategy and the sustainability of Ex-US growth, which contributed 47% of Q3 revenues with a 20% year-on-year increase. The rapid growth in Other Regulated Markets (ORM) at 21% YoY and Growth Markets at 19% YoY highlights the company's successful geographical diversification. The aspiration to mirror US revenue contribution from Ex-US markets within two years presents a significant growth opportunity but also an execution risk. Investors should monitor the pace of new product launches in the US and the competitive landscape across all key geographies in the upcoming quarters.